The earnings miss is secondary to the pipeline catalyst timeline. Monitor for REVEAL pivotal trial topline data and FDA feedback in 1H 2027, which will determine TSHA-102's BLA path. The $230M cash raise removes near-term dilution risk but increases the binary outcome sensitivity to the pivotal data.
Drug in focus
TSHA drug pipeline →TSHA-102
▲ Bullish Named in this press release- Impact
- Phase
- Pivotal (registrational)
- Time to market
- If the 1H 2027 pivotal data and FDA feedback are positive, a BLA submission could follow in 2027-2028, with potential approval in 2028-2029. This timeline depends on the regulatory pathway the FDA outlines.
- Next catalyst
- None dated
What to watchThe next major binary catalyst is the topline 6-month interim analysis from the REVEAL pivotal trial and FDA feedback on the BLA submission pathway, both expected in the first half of 2027. Positive data and regulatory alignment could open a clear path to approval and drive significant upside; negative data or FDA pushback would be a severe setback for this single-asset company.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 12 $6.41entry
- T+1 · 3mo ago −6.48%α −7.18% · $5.99
- T+5 · 3mo ago +0.39%α +0.83% · $6.43
- T+20 · 2mo ago −19.44%α −17.54% · $5.16
- T+60 · 12d ago −36.14%α −31.03% · $4.09
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Taysha Gene Therapies reported Q2 2026 EPS of -$0.13, missing consensus of -$0.11 by 18.2%, with zero revenue vs. $1.99M a year ago. The miss is overshadowed by completion of dosing in the pivotal REVEAL trial and a $230M follow-on offering extending cash runway into 2H 2028, with topline data and FDA feedback expected in 1H 2027. The stock's reaction will hinge on pipeline catalysts, not the quarterly financials.
Key Financial Metrics
Key Facts
- Completed dosing in REVEAL pivotal trial (17 patients) and ASPIRE trial (4 patients) for TSHA-102 in Rett syndrome.
- Topline data from 6-month interim analysis and FDA feedback on BLA pathway expected in 1H 2027.
- Completed $230M follow-on offering; cash and equivalents of $455.4M extend runway into 2H 2028.
- Q2 2026 net loss of $46.6M ($0.13/share) vs. consensus EPS of -$0.11; revenue was $0 vs. $1.99M in Q2 2025.
- TSHA-102 continues to be generally well tolerated with no severe treatment-related SAEs or DLTs across 33 patients.
Financial Impact
Q2 2026 net loss of $46.6M vs. $26.9M in Q2 2025; cash burn rate increased due to BLA-enabling manufacturing and clinical trial costs.
Risk Factors
- TSHA-102 pivotal trial data may fail to meet primary endpoint, jeopardizing BLA submission.
- Regulatory feedback from FDA could require additional trials, delaying approval and increasing costs.
- Cash runway into 2H 2028 assumes no further delays; any setback could necessitate additional dilutive financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3343130 |
Track record
14 reports on TSHA
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +20.50% at T+60 after the Jun 25, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $4.06 Now $4.06 −0.00% settles Feb 16
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $4.21 Now $4.06 −3.56% settles Feb 10
- Aug 11, 202613w ago Press Release Neutral 5/10 Viewing Entry $6.41 to $4.09 Now $4.06 −36.61% ▼ −36.14% −31.03% vs SPY
- Jun 25, 202620w ago 8-K Mixed 5/10 Entry $6.34 to $5.04 Now $4.06 −35.96% ▼ −20.50% −26.61% vs SPY
- Jun 25, 202620w ago 424B5 Bearish 6/10 Entry $6.34 to $5.04 Now $4.06 +35.96% ▲ +20.50% +26.61% vs SPY
- Jun 24, 202620w ago Press Release Bearish 7/10 Entry $6.21 to $5.02 Now $4.06 +34.62% ▲ +19.16% +22.89% vs SPY
- Jun 5, 202623w ago Press Release Neutral 2/10 Entry $5.50 to $5.69 Now $4.06 −26.18% ▲ +3.45% −0.55% vs SPY
- May 6, 202627w ago 8-K Neutral 5/10 No price data
- May 6, 202627w ago Press Release Mixed 7/10 Entry $6.98 to $5.86 Now $4.06 −41.83% ▼ −16.05% −18.11% vs SPY
- Apr 29, 202628w ago Press Release Neutral 1/10 Entry $6.27 to $5.52 Now $4.06 −35.25% ▼ −11.96% −16.07% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers